Expression of COX-1 and COX-2 mRNAs in atherosclerotic plaques

被引:49
作者
McGeer, PL [1 ]
McGeer, EG [1 ]
Yasojima, K [1 ]
机构
[1] Univ British Columbia, Dept Psychiat, Kinsmen Lab Neurol Res, Vancouver, BC V6T 1Z3, Canada
关键词
inflammation; arteries; cyclooxygenase; NSAIDs; cyclooxygenase-2; inhibitors; C-reactive protein;
D O I
10.1016/S0531-5565(02)00028-1
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 [法学]; 0303 [社会学]; 100203 [老年医学];
摘要
Inflammation is a characteristic of atherosclerotic plaques. Prostaglandins are inflammatory mediators whose production is controlled by cyclooxygenase (COX). There are two isoforms: COX-1 and COX-2. COX-1 is relatively stable while COX-2 is induced in inflammatory states. In order to evaluate their possible contribution to atherosclerotic plaque inflammation, we measured their relative levels in postmortem plaque and adjacent normal arterial tissue. Eleven pairs of atherosclerotic plaque and adjacent normal arterial tissue were obtained from postmortem specimens. Total RNA was extracted and relative levels of COX-1 and COX-2 determined by the technique of RT-PCR. COX-2 levels were 4.8-fold higher in plaque tissue than in normal artery. COX-1 levels were only 1.1-fold higher. There was no relationship between sex, age, postmortem delay or cause of death and COX-2 or COX-1 levels. COX-2 levels are sharply upregulated in atherosclerotic plaques, indicating that it may be a significant contributor to plaque inflammation. Accordingly, COX-2 inhibitors may reduce the degree of inflammation and protect against future cardiovascular events. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:925 / 929
页数:5
相关论文
共 15 条
[1]
BARTON AJL, 1993, J NEUROCHEM, V61, P127
[2]
NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection [J].
Boers, M .
LANCET, 2001, 357 (9264) :1222-1223
[3]
Crofford LJ, 1997, J RHEUMATOL, V24, P15
[4]
EXTENSIVE POSTMORTEM STABILITY OF RNA FROM RAT AND HUMAN-BRAIN [J].
JOHNSON, SA ;
MORGAN, DG ;
FINCH, CE .
JOURNAL OF NEUROSCIENCE RESEARCH, 1986, 16 (01) :267-280
[5]
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib [J].
Konstam, MA ;
Weir, MR ;
Reicin, A ;
Shapiro, D ;
Sperling, RS ;
Barr, E ;
Gertz, BJ .
CIRCULATION, 2001, 104 (19) :2280-2288
[6]
Risk of cardiovascular events associated with selective COX-2 inhibitors [J].
Mukherjee, D ;
Nissen, SE ;
Topol, EJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (08) :954-959
[7]
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events [J].
Ridker, PM ;
Rifai, N ;
Clearfield, M ;
Downs, JR ;
Weis, SE ;
Miles, JS ;
Gotto, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (26) :1959-1965
[8]
Mechanisms of disease - Atherosclerosis - An inflammatory disease [J].
Ross, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (02) :115-126
[9]
MESSENGER-RNA DEGRADATION IN EUKARYOTES [J].
SACHS, AB .
CELL, 1993, 74 (03) :413-421
[10]
Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials [J].
Sanmuganathan, PS ;
Ghahramani, P ;
Jackson, PR ;
Wallis, EJ ;
Ramsay, LE .
HEART, 2001, 85 (03) :265-271